🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pleasure to a be a part of this timely review examining the relevance and safety of psychedelic therapy for the treatment of personality pathology. Outstanding work Brennan, Rick Zeifman, and team.

CPCR Associate Center Director Dr. Albert Garcia-Romeu was interviewed on Texas Public Radio last week. He discusses how psychedelic research can be supported today. tpr.org/podcast/petrie…

Fertile ground for exploring the effect of psychedelics on sleep disturbance, including in the context of PTSD. Thanks for inviting me to be a part of this article: Dr. Matthew J Reid Robin Carhart-Harris Hannes Kettner

New post on apophenia - one of my favorite constructs

Interesting new study Many people fill out self-report measures of psychopathology and self-diagnose. Autism-spectrum has become very popular and sort of trendy. But it turns out that self-reported autism-spectrum barely correlates with clinician ratings: nature.com/articles/s4422…

New paper 🧵! Rebecca Ehrenkranz, PhD, MPH, David B. Yaden & I explore investigator-level biases in psychedelic clinical trials, & measures that have been proposed to mitigate them. We advocate for 4 additional measures that we believe may be particularly beneficial for the field to implement

Thank you Shereef Elnahal, MD for sharing our study!

Of greatest clinical relevance, 86% of studies found insight was associated with therapeutic benefit. Notably, the relationship was often stronger than mystical-type experiences, which have received more research attention.

.VA Secretary Doug Collins: "What we found, speaking of the last four years, is we found an Administration that wanted to throw money and people at problems... and we saw wait times stay the same... We saw disability claims skyrocket... Veterans are understanding now that we're putting them

Marianna Graziosi Frederick Barrett Robin Carhart-Harris Johns Hopkins Psychedelic Research Center Natalie Gukasyan, MD Ben Kelmendi Matthias E. Liechti Sandeep Nayak Katrin Preller Nathalie M. Rieser Brandon Weiss Max Wolff paper is here: researchgate.net/publication/38…

CPCR is hiring a postdoc to manage the operation of clinical drug trials focused on the treatment of PTSD with psychedelic therapy. Read more below!

Dr. Brandon Weiss (Brandon Weiss), Assistant Professor, contributed to a thoughtful and compassionate perspective to the "Military Voices" panel at last week's Federal Summit on Psychedelic Medicine, alongside Veterans Jay Kopelman, Dr. Leith States, and Rear Admiral (Ret.) Dr. James

Dr. John Krystal of #yalepsych and Yale School of Medicine spoke to HopkinsPsych about Lessons from ketamine: informing treatments for schizophrenia, depression, and PTSD. Event organized by CPCR Faculty Brandon Weiss Brandon Weiss

At Summit Behavioral Health's 'Tactical Recovery' Continuing Education event, Assistant Professor Dr. Brandon Weiss (Brandon Weiss) spoke to 150 clinicians about the ethical administration, risks, and benefits of psychedelic therapies. This session was specifically designed for mental

At the recent Psychedelic Therapeutics and Drug Development Conference, Assistant Professor Dr. Brandon Weiss served on a key panel, "Industry-Academic Collaboration: The Path to Success." Alongside fellow experts Dr. Amber Burch from Purisys, Dr. Dan Perkins of the University of

A great step toward standardizing reporting of extrapharmacologic factors in psychedelic trials! Congrats Chloé Pronovost-Morgan Leor Roseman 🦋 @leorroseman.bsky.social et al nature.com/articles/s4159…

🚨🍄 Major new preprint alert 🍄🚨 I think these will be important results. They are not going make me popular with my #psychedelic in-group, please do not shoot the messenger! The premise of this pre-registered meta analysis (osf.io/preprints/psya…) is that it is biased to